Immunotherapy for head and neck cancer: where do we go from here?

被引：0
|
作者：
Ko, Eric C. [1 ]
Hanna, Glenn J. [2 ]
机构：
[1] Univ Massachusetts, UMass Mem Med Ctr, Chan Med Sch, Dept Radiat Oncol, 55 Lake Ave North, Worcester, MA 01655 USA
[2] Harvard Med Sch, Dana Farber Canc Inst, Ctr Head & Neck Oncol, 450 Brookline Ave, Boston, MA 02215 USA
来源：
IMMUNOTHERAPY | 2023年
关键词：
cancer immunology; checkpoint inhibitors; head and neck squamous cell cancer; immunotherapy; radiotherapy; SQUAMOUS-CELL CARCINOMA; OPEN-LABEL; PEMBROLIZUMAB; CETUXIMAB; RECURRENT; CHEMOTHERAPY; MULTICENTER; NIVOLUMAB; CARE;
D O I：
10.2217/imt-2023-0191
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Immunotherapy for head and neck cancer shows promising new directions - and challenges ahead. What can we learn from recent trials to improve patient selection and optimize combination therapy?
引用
收藏
页码：1497 / 1500
页数：4
相关论文
共 50 条
  • [1] Immunotherapy in Head and Neck Cancer: Where Do We Stand?
    Vallianou, Natalia G.
    Evangelopoulos, Angelos
    Kounatidis, Dimitris
    Panagopoulos, Fotis
    Geladari, Eleni
    Karampela, Irene
    Stratigou, Theodora
    Dalamaga, Maria
    CURRENT ONCOLOGY REPORTS, 2023, 25 (08) : 897 - 912
  • [2] Chemo-immunotherapy and radiation in locally advanced head and neck cancer: Where do we stand?
    Belgioia, L.
    Becherini, C.
    Bacigalupo, A.
    Bonomo, P.
    ORAL ONCOLOGY, 2022, 127
  • [3] Immunotherapy for head and neck cancer: where are we now and where are we going?
    Bauml, Joshua M.
    Aggarwal, Charu
    Cohen, Roger B.
    ANNALS OF TRANSLATIONAL MEDICINE, 2019, 7
  • [4] Immunotherapy for osteosarcoma: Where do we go from here?
    Wedekind, Mary F.
    Wagner, Lars M.
    Cripe, Timothy P.
    PEDIATRIC BLOOD & CANCER, 2018, 65 (09)
  • [5] Combination immunotherapy: Where do we go from here?
    Overacre, Abigail E.
    Kurtulus, Sema
    Sznol, Mario
    Pardoll, Drew M.
    Anderson, Ana
    Vignali, Dario A. A.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2015, 3
  • [6] Immunotherapy for esophageal cancer: Where are we now and where can we go
    Shoji, Yoshiaki
    Koyanagi, Kazuo
    Kanamori, Kohei
    Tajima, Kohei
    Ogimi, Mika
    Ninomiya, Yamato
    Yamamoto, Miho
    Kazuno, Akihito
    Nabeshima, Kazuhito
    Nishi, Takayuki
    Mori, Masaki
    WORLD JOURNAL OF GASTROENTEROLOGY, 2024, 30 (19) : 2496 - 2501
  • [7] Stereotactic Body Radiation Therapy in Recurrent Head and Neck Cancer: Where Do We Stand?
    Nath, Jyotiman
    Neog, Moniprom
    Bhattacharyya, Mouchumee
    Kalita, Apurba Kumar
    INDIAN JOURNAL OF OTOLARYNGOLOGY AND HEAD & NECK SURGERY, 2024, 76 (2) : 2212 - 2215
  • [8] Immunotherapy in Head and Neck Cancer: Where Do We Stand?
    Natalia G. Vallianou
    Angelos Evangelopoulos
    Dimitris Kounatidis
    Fotis Panagopoulos
    Eleni Geladari
    Irene Karampela
    Theodora Stratigou
    Maria Dalamaga
    Current Oncology Reports, 2023, 25 : 897 - 912
  • [9] Immunotherapy in head and neck cancer: aiming at EXTREME precision
    Szturz, Petr
    Vermorken, Jan B.
    BMC MEDICINE, 2017, 15
  • [10] Where Do We (INDI)GO From Here?
    Kinslow, Connor J.
    Brown, Paul D.
    Iwamoto, Fabio M.
    Wu, Cheng-Chia
    Yu, James B.
    Cheng, Simon K.
    Wang, Tony J. C.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (02): : 330 - 333
12345